Solangepras (; developmental code name CVN-424), or solengepras (), is an inverse agonist of the orphan G protein-coupled receptor 6 (GPR6) which is under development for the treatment of Parkinson's disease. It is a small molecule and is taken by mouth. Solangepras produces hyperlocomotion and reverses haloperidol-induced catalepsy in rodents. It is being developed by Cerevance. As of October 2024, solangepras is in phase 3 clinical trials.